MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)

• CAT Number: I040878
• CAS Number: 2987937-38-0
• Molecular Formula: C46H47FN8O12
• Molecular Weight: 922.91
• Purity: ≥95%
• Synonyms: 6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[(19R)-19-ethyl-6-fluoro-19-hydroxy-10-(hydroxymethyl)-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-7-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide
• IUPAC Name: 6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[(19S)-19-ethyl-6-fluoro-19-hydroxy-10-(hydroxymethyl)-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-7-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide
• InChI: InChI=1S/C46H47FN8O12/c1-2-46(66)30-17-35-42-27(22-55(35)44(64)29(30)24-67-45(46)65)28(23-56)26-16-33(31(47)18-32(26)53-42)51-39(60)21-50-43(63)34(15-25-9-5-3-6-10-25)52-38(59)20-49-37(58)19-48-36(57)11-7-4-8-14-54-40(61)12-13-41(54)62/h3,5-6,9-10,12-13,16-18,34,56,66H,2,4,7-8,11,14-15,19-24H2,1H3,(H,48,57)(H,49,58)(H,50,63)(H,51,60)(H,52,59)/t34-,46+/m0/s1
• InChIKey: IQSVCRAHKRDQOX-HCPWKLSCSA-N
• SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC(=C(C=C5N=C4C3=C2)F)NC(=O)CNC(=O)[C@H](CC6=CC=CC=C6)NC(=O)CNC(=O)CNC(=O)CCCCCN7C(=O)C=CC7=O)CO)O

MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) (CAT: I040878) is a drug-linker conjugate designed for antibody-drug conjugates (ADC) applications. The conjugate features a cleavable MC-GGFG linker, which can be enzymatically cleaved by proteases in the tumor microenvironment, releasing the potent chemotherapy agent 11F-Camptothecin. This design allows for selective delivery of the cytotoxic drug to cancer cells, minimizing off-target effects and enhancing the therapeutic index. The 11F-Camptothecin, a topoisomerase I inhibitor, induces DNA damage and apoptosis in cancer cells. This compound is relevant for Cancer Disease Research, particularly in the development of targeted therapies for cancer treatment through ADC technology.